Difference between revisions of "Prothrombin complex concentrates"

(See Also)
(Adult Dosing)
Line 6: Line 6:
 
==Adult Dosing==
 
==Adult Dosing==
 
*Based on pretreatment INR, units based on factor 9 content
 
*Based on pretreatment INR, units based on factor 9 content
**INR2-<4: 25units/kg, not to exceed 2500 units
+
**INR 2-4: 25units/kg, not to exceed 2500 units
**INR4-<6: 35units/kg, not to exceed 3500 units
+
**INR 4-6: 35units/kg, not to exceed 3500 units
**INR>6: 50units/kg, not to exceed 5000 units
+
**INR >6: 50units/kg, not to exceed 5000 units
 +
 
 
==Pediatric Dosing==
 
==Pediatric Dosing==
 
Safety and efficacy not established
 
Safety and efficacy not established

Revision as of 17:57, 28 May 2015

General

  • Type: Hemostatics, blood components
  • Dosage Forms:lypophilized concentrate for reconstitution 500u/vial and 1000u/vial
  • Common Trade Names: Kcentra

Adult Dosing

  • Based on pretreatment INR, units based on factor 9 content
    • INR 2-4: 25units/kg, not to exceed 2500 units
    • INR 4-6: 35units/kg, not to exceed 3500 units
    • INR >6: 50units/kg, not to exceed 5000 units

Pediatric Dosing

Safety and efficacy not established

Special Populations

  • Pregnancy Rating: C
  • Lactation: Unknown, breast feeding not advised
  • Renal Dosing
    • Adult-N/A
    • Pediatric-N/A
  • Hepatic Dosing
    • Adult-N/A
    • Pediatric-N/A

Contraindications

  • Allergy to class/drug
  • DIC
  • known HIT (Heparin induced thrombocytopenia)

Serious

  • thromboembolism
  • blood product (hepatitis, HIV)

Common

  • thromboembolic events (8.7%)
  • headache (7.8%)
  • hypotension (4.9%)
  • nausea/vomiting
  • arthralgia
  • ICH (2.9%)
  • mental status change (2.9%)
  • hypertension (2.9%)

Pharmacology

  • Half-life:
  • Metabolism:
  • Excretion:
  • Mechanism of Action:

See Also

Sources

Medscape